Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00101816
Registration number
NCT00101816
Ethics application status
Date submitted
13/01/2005
Date registered
14/01/2005
Date last updated
10/08/2010
Titles & IDs
Public title
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Query!
Scientific title
A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Query!
Secondary ID [1]
0
0
CA180-006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Myeloid Leukemia
0
0
Query!
Blast Crisis
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dasatinib
Experimental: 1 -
Treatment: Drugs: Dasatinib
Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Major and Overall Hematologic Response (MaHR and OHR)
Query!
Assessment method [1]
0
0
MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). Criteria for MaHR are specified in Outcome Measure 2. OHR=best confirmed response of MaHR or minor HR (MiHR). MiHR= \<15% blasts in bone marrow and \<15% blasts in peripheral blood (PB); \<30% blasts + promyelocytes in bone marrow and \<30% blasts + promyelocytes in PB; \<20% basophils in PB; no extramedullary disease other than spleen and liver. Confirmed hematologic response=response confirmed =4 weeks after first documented event with no concomitant use of anagrelide or hydroxyurea.
Query!
Timepoint [1]
0
0
Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment
Query!
Secondary outcome [1]
0
0
Median Duration of Major Hematologic Response (MaHR)
Query!
Assessment method [1]
0
0
MaHR=best confirmed response of CHR or NEL. CHR=white blood cells = institutional upper limit of normal (iULN); absolute neutrophil count (ANC) =1000/mm3; platelets =100,000/mm3; no blasts/promyelocytes in peripheral blood (PB); bone marrow blasts =5%; \<5% myelocytes+metamyelocytes in PB; PB basophils = iULN; no extramedullary involvement. NEL=WBC = iULN; no blasts/promyelocytes in PB; bone marrow blasts =5%; \<5% myelocytes+metamyelocytes in PB; PB basophils = iULN; no extramedullary involvement; at least 1 of the following: ANC =500/mm3 \& \<1000/mm3; platelets =20,000/mm3 \& \<100,000/mm3.
Query!
Timepoint [1]
0
0
Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment
Query!
Secondary outcome [2]
0
0
Median Duration of Overall Hematologic Response (OHR)
Query!
Assessment method [2]
0
0
OHR=best confirmed response of MaHR or MiHR. MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). Criteria for MaHR are specified in Outcome Measure 2. Criteria for MiHR are specified in Outcome Measure 1. Maintaining a response was defined as no 2 consecutive records of non-response (ie, a single record of non-response between 2 assessments of response was not considered a loss of response).
Query!
Timepoint [2]
0
0
Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment
Query!
Secondary outcome [3]
0
0
Time to MaHR and OHR
Query!
Assessment method [3]
0
0
Median time from first dosing to date of OHR and/or MaHR in subjects who achieved OHR and MaHR. MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). OHR=best confirmed response of MaHR or minor hematologic response (MiHR). Criteria for MaHR are specified in Outcome Measure 2. Criteria for MiHR are specified in Outcome Measure 1.
Query!
Timepoint [3]
0
0
Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment
Query!
Secondary outcome [4]
0
0
Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response
Query!
Assessment method [4]
0
0
Best confirmed cytogenetic response. Determination of cytogenetic response is based on the prevalence (percentage) of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase in a bone marrow sample (aspirates/biopsies).
Query!
Timepoint [4]
0
0
Baseline (within 4 weeks of therapy start); Every month for Cycles 1-3; Every 12 weeks for Cycles 4+; end of treatment
Query!
Secondary outcome [5]
0
0
Number of Participants With CHR or NEL, MiHR, or no Hematologic Response
Query!
Assessment method [5]
0
0
Best confirmed hematologic response. Confirmed hematologic response=response that is confirmed after at least 4 weeks with no concomitant use of anagrelide or hydroxyurea use during this interval. Criteria for complete hematologic response (CHR) or No Evidence of Leukemia (NEL) are specified in Outcome Measure 2. Criteria for minor hematologic response (MiHR) are specified in Outcome Measure 1.
Query!
Timepoint [5]
0
0
Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycles 1 and 2; After every 2nd cycle for Cycles 3+; at end of treatment
Query!
Secondary outcome [6]
0
0
Number of Participants Achieving Major Molecular Response (MMR)
Query!
Assessment method [6]
0
0
Number of participants who achieved an MMR at any time during the treatment period. MMR was calulated by measuring BCR-ABL transcripts in blood during treatment using quantitative reverse transcription-polymerase chain reaction (RT-PCR). BCR-ABL=the fused gene found in subjects with this type of Chronic Myeloid Leukemia (CML).
Query!
Timepoint [6]
0
0
Baseline, every 12 weeks, and at time of Complete Cytogenetic Response (CCyR) for quantitative Polyermase Chain Reaction (qPCR) analysis
Query!
Secondary outcome [7]
0
0
MaHR and Major Cytogenetic Response (MCyR) Among Participants With Baseline BCR-ABL Point Mutations
Query!
Assessment method [7]
0
0
MaHR and MCyR in subjects with mutations at baseline, including imatinib-resistant mutations (IRM) and specific BCR-ABL mutations (SBAM). Criteria for MaHR are specified in Outcome Measure 2. MCyR=rate of complete cytogenetic responses + the rate of partial cytogenetic responses, as defined in Outcome Measure 5. BCR-ABL=the fused gene found in subjects with this type of CML. This table contains those mutations observed in at least 3 participants. The categories "1 IRM w/2-4-fold increase in resistance" and "=1 IRM w/=5-fold increase in resistance" refer to increase in resistance to imatinib.
Query!
Timepoint [7]
0
0
baseline, at time of disease progression
Query!
Secondary outcome [8]
0
0
Minimally Significant Changes From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G)
Query!
Assessment method [8]
0
0
Number of subjects with minimally significant changes from baseline in the health-related quality of life questionnaire FACT-G. FACT-G=27 questions in 4 domains: physical, social/family, emotional, \& functional well-being (PWB, SWB, EWB, FWB). Score range: 0-108; higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, \& FWB score change of 3 or more, \& SWB score change of 2 or more=minimal clinical important change.
Query!
Timepoint [8]
0
0
Baseline, Every 2 weeks for the first 3 cycles, following every 4-week cycle, and once at follow-up
Query!
Secondary outcome [9]
0
0
Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), AEs Leading to Discontinuation, Drug-Related AEs
Query!
Assessment method [9]
0
0
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
Query!
Timepoint [9]
0
0
Continuously throughout study, from pre-treatment visit through end of study (due to death, unacceptable toxicity, treatment failure, etc) and follow-up period
Query!
Secondary outcome [10]
0
0
Pharmacokinetics (PK) of Dasatinib - Maximum Observed Plasma Concentration (Cmax)
Query!
Assessment method [10]
0
0
The Cmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared.
Query!
Timepoint [10]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [11]
0
0
Pharmacokinetics (PK) of Dasatinib - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h or 24 h(AUC[0-T])
Query!
Assessment method [11]
0
0
The AUC(0-T) was calculated using the mixed log-linear trapezoidal algorithm in Kinetica™. In the calculation of AUC(0-T), predose concentrations that were \< lower limit of qualtitation were assigned a value of zero.
Query!
Timepoint [11]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [12]
0
0
Pharmacokinetics (PK) of Dasatinib - Time to Maximum Observed Plasma Concentration (Tmax)
Query!
Assessment method [12]
0
0
The Tmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared.
Query!
Timepoint [12]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [13]
0
0
Pharmacokinetics (PK) of Dasatinib - Plasma Half-life (T-HALF)
Query!
Assessment method [13]
0
0
The T-HALF was calculated as Ln2/Lz,where Lz was the absolute value of the slope of the terminal log-linear phase.
Query!
Timepoint [13]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [14]
0
0
Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Maximum Observed Plasma Concentration (Cmax)
Query!
Assessment method [14]
0
0
The Cmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared.
Query!
Timepoint [14]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [15]
0
0
Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h (AUC[0-T])
Query!
Assessment method [15]
0
0
The AUC(0-T) was calculated using the mixed log-linear trapezoidal algorithm in Kinetica™. In the calculation of AUC(0-T), predose concentrations that were less than the lower limit of quantitation (LLQ) were assigned a value of zero.
Query!
Timepoint [15]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [16]
0
0
Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Time to Maximum Observed Plasma Concentration (Tmax)
Query!
Assessment method [16]
0
0
The Tmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared.
Query!
Timepoint [16]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [17]
0
0
Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Plasma Half-life (T-HALF)
Query!
Assessment method [17]
0
0
The T-HALF was calculated as Ln2/Lz,where Lz was the absolute value of the slope of the terminal log-linear phase.
Query!
Timepoint [17]
0
0
Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.
Query!
Secondary outcome [18]
0
0
Population PK of Dasatinib
Query!
Assessment method [18]
0
0
Population pharmacokinetic analysis was not done because it is not meaningful for this single study
Query!
Timepoint [18]
0
0
Day 8 immediately prior to the first daily dose and between 30 minutes to 3 hours following this dose.
Query!
Eligibility
Key inclusion criteria
* Subjects with myeloid blast phase chronic myeloid leukemia
* Subjects who are either resistant or intolerant of imatinib mesylate
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subjects who are eligible and willing to undergo transplantation
* Serious uncontrolled medical disorder or active infection
* Uncontrolled or significant heart problems, such as congestive heart failure, recent heart attack, etc
* Subjects receiving medications that may affect heart rhythm
* Other malignancy/cancer other than CML
* History of significant bleeding disorder unrelated to CML
* Pregnant or breastfeeding women (subjects must avoid becoming pregnant)
* Subjects received imatinib within 7 days, interferon or cytarabine within 14 days, a targeted anticancer medication within 14 days, an antineoplastic agent (other than hydroxyurea or anagrelide) within 28 days, or any other investigation medication in 28 days
* Subject is receiving medications that affect platelet function or an anticoagulant
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
124
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
Local Institution - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oregon
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Wien
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
B-Leuven
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Edegem
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Aarhus
Query!
Country [24]
0
0
Finland
Query!
State/province [24]
0
0
Helsinki
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Lille
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lyon Cedex 03
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Nantes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris Cedex 10
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Pessac
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Poitiers Cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Strasbourg Cedex
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hamburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Mainz
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Mannheim
Query!
Country [35]
0
0
Israel
Query!
State/province [35]
0
0
Ramat-Gan
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Bologna
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Napoli
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Orbassano
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Roma
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Jeollanam-Do
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Kyunggi-Do
Query!
Country [42]
0
0
Korea, Republic of
Query!
State/province [42]
0
0
Seoul
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
Nijmegen
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Rotterdam
Query!
Country [45]
0
0
Norway
Query!
State/province [45]
0
0
Trondheim
Query!
Country [46]
0
0
Philippines
Query!
State/province [46]
0
0
Quezon City
Query!
Country [47]
0
0
Singapore
Query!
State/province [47]
0
0
Singapore
Query!
Country [48]
0
0
Sweden
Query!
State/province [48]
0
0
Gothenburg
Query!
Country [49]
0
0
Sweden
Query!
State/province [49]
0
0
Lund
Query!
Country [50]
0
0
Sweden
Query!
State/province [50]
0
0
Umea
Query!
Country [51]
0
0
Sweden
Query!
State/province [51]
0
0
Uppsala
Query!
Country [52]
0
0
Switzerland
Query!
State/province [52]
0
0
Basel
Query!
Country [53]
0
0
Taiwan
Query!
State/province [53]
0
0
Taipei
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Taoyuan
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Central
Query!
Country [56]
0
0
United Kingdom
Query!
State/province [56]
0
0
Greater London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are currently in the myeloid blast phase of chronic myeloid leukemia (CML) and who are either resistant to or intolerant of imatinib mesylate. Another purpose of the study is to see what side effects this drug may have on subjects.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00101816
Query!
Trial related presentations / publications
Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15;109(8):3207-13. doi: 10.1182/blood-2006-09-046888. Epub 2006 Dec 21. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00101816
Download to PDF